ECDNA

Boundless Bio Announces Upcoming Presentation at the American Association for Cancer Research Annual Meeting 2022

Retrieved on: 
Wednesday, March 9, 2022
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, AACR, American Association for Cancer Research, Therapy, Survival, Oncogene, Cancer, Association, Chromosome, DNA, Rolling circle replication, Radiation, Patient, American Association, Bio, Cell division, Immunotherapy, Growth, Neoplasm, Recurrence, Medical imaging, Vaccine, ecDNA, Boundless Bio, ECDNA, BOUNDLESS BIO

Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced plans to present at the American Association for Cancer Research (AACR) Annual Meeting 2022, held in New Orleans and virtually from April 8-13, 2022.

Key Points: 
  • Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced plans to present at the American Association for Cancer Research (AACR) Annual Meeting 2022, held in New Orleans and virtually from April 8-13, 2022.
  • The in-person poster presentation reveals a novel association between ecDNA bearing tumors and high replication stress, presenting a potential therapeutic strategy for ecDNA-enabled oncogene amplified cancers.
  • ecDNA replicate within cancer cells and, due to their lack of centromeres, can be asymmetrically passed to daughter cells during cell division, leading to focal gene amplification and copy number heterogeneity in cancer.
  • Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with oncogene amplified cancers.

Boundless Bio Presents Data on Extrachromosomal DNA (ecDNA) Driven Resistance to KRASG12C Inhibitors at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021

Retrieved on: 
Thursday, October 7, 2021
Oncology, Health, Genetics, Research, Science, Biotechnology, Neoplasm, Harvard Medical School, EGFR, George M. Low Center for Industrial Innovation, Rolling circle replication, Fluorescence, Chromosome, Conference, Poster, Survival, FISH, Growth, Cancer, In situ hybridization, Dana–Farber Cancer Institute, KRAS, Kinetics, Radiation, Assistant, Bio, Immunotherapy, AACR, FGFR, Therapy, Cell division, DNA, Recurrence, Oncogene, Patient, Clinical trial, NGS, Colorectal cancer, Vaccine, Pharmaceutical industry, Medical imaging, ecDNA, Boundless Bio, ECDNA, BOUNDLESS BIO

Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA in aggressive cancers, today will present a poster at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics.

Key Points: 
  • Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA in aggressive cancers, today will present a poster at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics.
  • The poster, LBA005: Detection of KRAS amplification on extrachromosomal DNA (ecDNA) upon acquired resistance to KRASG12C inhibitors , is available to registered attendees starting at 9AM EST today.
  • ecDNA driven oncogene copy number amplifications, a mechanism that is distinct from second site mutations, is a frequent cause of resistance in cancer cells.
  • Boundless Bio, in collaboration with the Dana-Farber Cancer Institute and Mirati Therapeutics, has shown that, in colorectal patients treated with KRASG12C inhibitors, ecDNA based amplification played an important role in resistance to KRASG12C inhibitor therapy.

Boundless Bio Announces Upcoming Presentation at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021

Retrieved on: 
Wednesday, September 22, 2021
Oncology, Health, Genetics, Clinical Trials, Research, Science, Biotechnology, Rolling circle replication, Cancer, Radiation, Dana–Farber Cancer Institute, Recurrence, Therapy, Conference, DNA, Dana, FDA, Patient, AACR, Bio, Immunotherapy, Cell division, Colorectal cancer, Survival, Oncogene, Pharmaceutical industry, Vaccine, ecDNA, Boundless Bio, ECDNA, BOUNDLESS BIO

Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced plans to present at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, held virtually from October 7-10, 2021.

Key Points: 
  • Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced plans to present at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, held virtually from October 7-10, 2021.
  • These findings support previous Boundless Bio published work that ecDNA is an important underlying cause of cancer resistance and reinforces the critical need for novel therapeutic strategies to address ecDNA enabled cancers.
  • ecDNA replicate within cancer cells and can be passed to daughter cells asymmetrically during cell division, thereby constituting a primary driver of focal gene amplification and copy number heterogeneity in cancer.
  • Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

Boundless Bio Raises Oversubscribed $105 Million Series B Financing to Advance Next-Generation Precision Oncology Therapies Directed Against Extrachromosomal DNA (ecDNA)

Retrieved on: 
Wednesday, April 28, 2021
Biotechnology, Health, Oncology, Clinical trials, Boundless, Cancer, Boundless Bio, ecDNA, Boundless Bio’s Spyglass™ Platform, BOUNDLESS BIO, ECDNA, BOUNDLESS BIO’S SPYGLASS™ PLATFORM

b'Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced the closing of an oversubscribed $105 Million Series B financing.

Key Points: 
  • b'Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced the closing of an oversubscribed $105 Million Series B financing.
  • In conjunction with the financing, Jakob Loven, Ph.D., Partner at Nextech Invest, will join the Boundless Bio Board of Directors.\n\xe2\x80\x9cBoundless Bio has made tremendous progress since launching in 2019,\xe2\x80\x9d said Zachary Hornby, President and Chief Executive Officer of Boundless Bio.
  • From these efforts, we have discovered and validated three ecDNA-essential targets and have initiated drug discovery against each.
  • \xe2\x80\x9cecDNA is a transformative new area of cancer biology, and Boundless Bio is the clear leader in the rapidly emerging field.